{"id":481935,"date":"2020-04-30T11:24:02","date_gmt":"2020-04-30T11:24:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=481935"},"modified":"2020-04-30T11:24:02","modified_gmt":"2020-04-30T11:24:02","slug":"alopecia-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/alopecia-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_481935.html","title":{"rendered":"Alopecia Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight"},"content":{"rendered":"

DelveInsight has launched a new report on Cold Agglutinin Disease Market Insights, Epidemiology and Market Forecast-2030<\/strong><\/p>\n

DelveInsight’s Alopecia  Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Alopecia  epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/span><\/p>\n

Hair loss, also knownas alopecia orbaldness, refers toa loss of hair from part of thehead or body.Typically,atleasttheheadisinvolved,andtheseverityofhairlosscanvaryfromasmall areatotheentirebody. About one-third of women experience hair loss at some time in their lives; among postmenopausal women, as many as two-thirds suffer hair thinning or bald spots. Hairloss in women often has a greater impact than hair loss does on men, because it is less socially acceptableforthem.Alopeciacanseverelyaffectawoman’semotionalwell-beingandquality oflif.<\/span><\/p>\n

                                                      \"\"<\/span><\/p>\n

 <\/p>\n

Click Here- Free sample page<\/a><\/strong><\/p>\n

Epidemiology<\/strong><\/p>\n

The Alopecia <\/span>epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Alopecia  epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Alopecia epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.<\/p>\n

Report key facts-<\/strong><\/p>\n

1. As per the study by Severi et al. titled, “Androgenetic alopecia in men aged 40–69 years: prevalence and risk factors,” the prevalence of vertex and full androgenic alopecia increased with age from approximately 30% (age 40–55 years) to 50% (age65–69years.<\/p>\n

2. According to the National Alopecia Areata Foundation,alopeciaareataaffectsasmanyas6.8 million people in the US with a lifetime risk of 2.1%. People of all ages, both sexes and all ethnic groups can develop alopecia are ata.<\/p>\n

 3. As per the article by Whiting et al. titled, “Cicatricial alopecia: clinicopathological findings and treatment,” the prevalence of cicatricial alopeciaintheUSis7%.<\/p>\n

Some of key companies are working on this disease which are given below-<\/strong><\/p>\n

1. Merck Pharma Co.<\/p>\n

2. Johnson & Johnson Co. <\/p>\n

3. Samumed<\/p>\n

Name of drugs covered which are given below-<\/strong><\/p>\n

1. Propecia (finasteride)<\/p>\n

2. Rogaine (Minoxidil)<\/p>\n

3.  SM04554<\/p>\n

Table of content<\/a><\/p>\n

1. Key Insights<\/span><\/p>\n

2. Executive Summary of Alopecia<\/span><\/p>\n

3. Competitive Intelligence Analysis for Alopecia<\/span><\/p>\n

4. Alopecia: Market Overview at a Glance<\/span><\/p>\n

4.1. Alopecia Total Market Share (%) Distribution in 2017<\/span><\/p>\n

4.2. Alopecia Total Market Share (%) Distribution in 2030<\/span><\/p>\n

5. Alopecia: Disease Background and Overview<\/span><\/p>\n

5.1. Introduction<\/span><\/p>\n

5.2. Sign and Symptoms <\/span><\/p>\n

5.3. Pathophysiology <\/span><\/p>\n

5.4. Risk Factors <\/span><\/p>\n

5.5. Diagnosis <\/span><\/p>\n

6. Patient Journey<\/span><\/p>\n

7. Alopecia Epidemiology and Patient Population<\/span><\/p>\n

7.1. Epidemiology Key Findings<\/span><\/p>\n

7.2. Assumptions and Rationale: 7MM<\/span><\/p>\n

7.3. Epidemiology Scenario: 7MM<\/span><\/p>\n

7.3.1. Alopecia Epidemiology Scenario in the 7MM (2017-2030)<\/span><\/p>\n

7.4. United States Epidemiology<\/span><\/p>\n

7.4.1. Alopecia Epidemiology Scenario in the United States (2017-2030)<\/span><\/p>\n

7.5. EU-5 Country-wise Epidemiology<\/span><\/p>\n

7.5.1. Germany Epidemiology<\/span><\/p>\n

7.5.1.1. Alopecia Epidemiology Scenario in Germany (2017-2030)<\/span><\/p>\n

7.5.2. France Epidemiology<\/span><\/p>\n

7.5.2.1. Alopecia Epidemiology Scenario in France (2017-2030)<\/span><\/p>\n

7.5.3. Italy Epidemiology<\/span><\/p>\n

7.5.3.1. Alopecia Epidemiology Scenario in Italy (2017-2030)<\/span><\/p>\n

7.5.4. Spain Epidemiology<\/span><\/p>\n

7.5.4.1. Alopecia Epidemiology Scenario in Spain (2017-2030)<\/span><\/p>\n

7.5.5. United Kingdom Epidemiology<\/span><\/p>\n

7.5.5.1. Alopecia Epidemiology Scenario in the United Kingdom (2017-2030)<\/span><\/p>\n

7.5.6. Japan Epidemiology<\/span><\/p>\n

7.5.6.1. Alopecia Epidemiology Scenario in Japan (2017-2030)<\/span><\/p>\n

8. Treatment Algorithm, Current Treatment, and Medical Practices<\/span><\/p>\n

8.1. Alopecia Treatment and Management<\/span><\/p>\n

8.2. Alopecia Treatment Algorithm <\/span><\/p>\n

9. Unmet Needs<\/span><\/p>\n

10. Key Endpoints of Alopecia Treatment<\/span><\/p>\n

11. Marketed Products<\/span><\/p>\n

11.1. List of Marketed Products in the 7MM<\/span><\/p>\n

11.2. Drug Name: Company Name<\/span><\/p>\n

11.2.1. Product Description<\/span><\/p>\n

11.2.2. Regulatory Milestones<\/span><\/p>\n

11.2.3. Other Developmental Activities<\/span><\/p>\n

11.2.4. Pivotal Clinical Trials<\/span><\/p>\n

11.2.5. Summary of Pivotal Clinical Trial<\/span><\/p>\n

12. Emerging Therapies<\/p>\n

12.1. Key Cross<\/span><\/p>\n

12.2. Drug Name: Company Name<\/span><\/p>\n

12.2.1. Product Description<\/span><\/p>\n

12.2.2. Other Developmental Activities<\/span><\/p>\n

12.2.3. Clinical Development<\/span><\/p>\n

12.2.4. Safety and Efficacy<\/span><\/p>\n

12.2.5. Product Profile<\/span><\/p>\n

13. Alopecia: Seven Major Market Analysis<\/p>\n

13.1. Key Findings<\/span><\/p>\n

13.2. Alopecia Market Size in 7MM<\/span><\/p>\n

13.3. Alopecia Market Size by Therapies in the 7MM<\/span><\/p>\n

14. Attribute analysis<\/span><\/p>\n

15. 7MM: Market Outlook<\/span><\/p>\n

15.1. United States: Market Size<\/span><\/p>\n

15.1.1. Alopecia Total Market Size in the United States<\/span><\/p>\n

15.1.2. Alopecia Market Size by Therapies in the United States<\/span><\/p>\n

15.2. EU-5 countries: Market Size and Outlook<\/span><\/p>\n

15.3. Germany Market Size<\/span><\/p>\n

15.3.1. Alopecia Total Market Size in Germany<\/span><\/p>\n

15.3.2. Alopecia Market Size by Therapies in Germany<\/span><\/p>\n

15.4. France Market Size<\/span><\/p>\n

15.4.1. Alopecia Total Market Size in France<\/span><\/p>\n

15.4.2. Alopecia Market Size by Therapies in France<\/span><\/p>\n

15.5. Italy Market Size<\/span><\/p>\n

15.5.1. Alopecia Total Market Size in Italy<\/span><\/p>\n

15.5.2. Alopecia Market Size by Therapies in Italy<\/span><\/p>\n

15.6. Spain Market Size<\/span><\/p>\n

15.6.1. Alopecia Total Market Size in Spain<\/span><\/p>\n

15.6.2. Alopecia Market Size by Therapies in Spain<\/span><\/p>\n

15.7. United Kingdom Market Size<\/span><\/p>\n

15.7.1. Alopecia Total Market Size in the United Kingdom<\/span><\/p>\n

15.7.2. Alopecia Market Size by Therapies in the United Kingdom<\/span><\/p>\n

15.8. Japan Market Outlook<\/span><\/p>\n

15.8.1. Japan Market Size<\/span><\/p>\n

15.8.2. Alopecia Total Market Size in Japan<\/span><\/p>\n

15.8.3. Alopecia Market Size by Therapies in Japan<\/span><\/p>\n

16. Access and Reimbursement Overview of Alopecia<\/span><\/p>\n

17. KOL Views<\/span><\/p>\n

18. Market Drivers<\/span><\/p>\n

19. Market Barriers<\/span><\/p>\n

20. Appendix<\/span><\/p>\n

20.1. Bibliography<\/span><\/p>\n

20.2. Report Methodology<\/span><\/p>\n

21. DelveInsight Capabilities<\/span><\/p>\n

22. Disclaimer<\/span><\/p>\n

23. About DelveInsight<\/span><\/p>\n

Why should you buy this report?<\/strong><\/p>\n